---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001548"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:27:07.702073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV

## Summary
- Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.
- NASH candidate ALG-055009 Phase 1 data positive; on track for Phase 2 filing by end 2023.
- COVID-19 candidate ALG-097558 to enter clinic in Q2 2023; top line data expected Q4 2023.
- HBV CAM-E ALG-000184 shows HBsAg reductions; 48-week data expected in 2023.
- HBV siRNA ALG-125755 SAD in healthy volunteers completed; now evaluating in CHB subjects.

## SEC filing metadata
- accession: 0001171843-23-001548
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/0001171843-23-001548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/f8k_030923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001548
- JSON: https://secwatch.observer/filing/0001171843-23-001548.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001548.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported the fourth quarter and full year 2022 results: net income Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha, EPS $(0.51).
  - Period: the fourth quarter and full year 2022
  - Net income: Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common sha
  - EPS: $(0.51)
  - Result: reported results
  source text: Net losses for the three months ended December 31, 2022, were $21.9 million or basic and diluted net loss per common share of $(0.51), compared to net losses of $37.7 million or basic and diluted net loss per common share of $(0.89) for the three months ended December 31, 2021. Net losses for the year ended December 31, 2022, were $96.0 million or basic and diluted net loss per common share of $(2.25), compared to net losses of $128.3 million or basic and diluted net loss per common share of $(3.22) for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184323001548/0001171843-23-001548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.